R S Geary
Overview
Explore the profile of R S Geary including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
32
Citations
386
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
El-Hamamsy D, Geary R, Gurol-Urganci I, van der Meulen J, Tincello D
J Robot Surg
. 2021 Feb;
16(1):81-88.
PMID: 33590420
This was a retrospective study to review the uptake and outcomes of robotic gynaecological surgery in England between 1st April 2006 and 31st March 2018, analysing Hospital Episode Statistics form...
2.
Geary R, Knight H, Carroll F, Gurol-Urganci I, Morris E, Cromwell D, et al.
BJOG
. 2017 Nov;
125(7):857-865.
PMID: 29105913
Tweetable Abstract: How to develop maternity indicators from administrative data.
3.
Miner Jr P, Geary R, Matson J, Chuang E, Xia S, Baker B, et al.
Aliment Pharmacol Ther
. 2006 May;
23(10):1427-34.
PMID: 16669957
Background: Alicaforsen is a phosphorothioate-modified antisense oligodeoxynucleotide designed to sequence-specifically reduce intercellular adhesion molecule 1 messenger RNA levels. Aims: To determine the systemic and local bioavailability of alicaforsen, and its...
4.
Raoof A, Chiu P, Ramtoola Z, Cumming I, Teng C, Weinbach S, et al.
J Pharm Sci
. 2004 May;
93(6):1431-9.
PMID: 15124202
In vivo study was performed to determine the tolerability and pharmacokinetics of ISIS 104838, a phosphorothioate antisense oligonucleotide targetting human tumour necrosis factor alpha (TNF-alpha) mRNA, following multi-dose administration via...
5.
Henry S, Geary R, Yu R, Levin A
Curr Opin Investig Drugs
. 2002 Mar;
2(10):1444-9.
PMID: 11890363
Antisense technology has progressed beyond the point of using only phosphorothioate oligodeoxynucleotides as therapeutic agents to looking at antisense molecules that contain additional chemical modifications as the next generation of...
6.
Cunningham C, Holmlund J, Geary R, Kwoh T, Dorr A, Johnston J, et al.
Cancer
. 2001 Sep;
92(5):1265-71.
PMID: 11571742
Background: Abnormal expression of Ras proteins frequently is found with oncogenic transformation making ras a promising therapeutic target. ISIS 2503 is a 20-base antisense phosphorothioate oligodeoxyribonucleotide that specifically downregulates H-ras...
7.
Geary R, Yu R, Levin A
Curr Opin Investig Drugs
. 2001 Sep;
2(4):562-73.
PMID: 11566019
Phosphorothioate (PS) oligodeoxynucleotides represent the class of antisense drugs most advanced in development and clinical testing. Exploitation of antisense oligonucleotide technology for development of rationally designed therapeutic drugs has presented...
8.
Geary R, Khatsenko O, Bunker K, Crooke R, Moore M, Burckin T, et al.
J Pharmacol Exp Ther
. 2001 Feb;
296(3):898-904.
PMID: 11181922
Three modified 20-mer antisense oligonucleotides targeted to human intercellular adhesion molecule-1 mRNA were characterized for their presystemic stability and oral bioavailability compared with a first-generation phosphorothioate oligodeoxynucleotide (PS ODN), ISIS...
9.
Geary R, Watanabe T, Truong L, Freier S, Lesnik E, Sioufi N, et al.
J Pharmacol Exp Ther
. 2001 Feb;
296(3):890-7.
PMID: 11181921
Plasma pharmacokinetics, biodistribution, excretion, and metabolism of four modified 20-mer antisense oligonucleotides targeted to human intercellular adhesion molecule-1 mRNA have been characterized in rats and compared with a first-generation phosphorothioate...
10.
Yu R, Geary R, Leeds J, Watanabe T, Moore M, Fitchett J, et al.
J Pharm Sci
. 2001 Feb;
90(2):182-93.
PMID: 11169535
The plasma pharmacokinetics and tissue disposition of ISIS 2503 were studied in mice following single and multiple bolus intravenous (iv) injections of 1-50 mg/kg, and in monkeys following single and...